Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature

Dmitry Victorovich Garbuzenko,Nikolay Olegovich Arefyev
DOI: https://doi.org/10.1111/jebm.12407
2020-10-09
Abstract:<p>All patients with liver cirrhosis and portal hypertension should be stratified by risk groups to individualize different therapeutic strategies to increase the effectiveness of treatment. In this regard, the development of primary prophylaxis of variceal bleeding and its management according to the severity of portal hypertension may be promising. This paper is to describe the modern principles of primary prophylaxis of esophageal variceal bleeding in patients with liver cirrhosis. The PubMed and EMbase databases, Web of Science, Google Scholar, and the Cochrane Database of Systematic Reviews were used to search for relevant publications from 1999 to 2019. The results suggested that depending on the severity of portal hypertension, patients with cirrhosis should be divided into those who need preprimary prophylaxis, which aims to prevent the formation of esophageal varices, and those who require measures that aim to prevent esophageal variceal bleeding. In subclinical portal hypertension, therapy should be etiological and pathogenetic. Cirrhosis with clinically significant portal hypertension should receive nonselective β‐blockers if they have small esophageal varices and risk factors for variceal bleeding. Nonselective β‐blockers are the first‐line drugs for the primary prevention of bleeding from medium to large‐sized esophageal varices. Endoscopic band ligation is indicated for the patients who are intolerant to nonselective β‐blockers or in the case of contraindications to pharmacological therapy. In summary, the stratification of cirrhotic patients by the severity of portal hypertension and an individual approach to the choice of treatment may increase the effectiveness of therapy as well as improve survival rate of these patients.</p>
medicine, general & internal
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the primary prevention strategy for preventing esophageal variceal bleeding in patients with liver cirrhosis. Specifically, the paper aims to describe the modern primary prevention principles for preventing esophageal variceal bleeding in patients with liver cirrhosis, stratify patients according to the severity of portal hypertension, individualize different treatment strategies, and thus improve the effectiveness of treatment. By reviewing relevant literature from 1999 to 2019, the paper explored the effects of different treatment methods, especially the role of non - selective beta - blockers (NSBBs) in preventing medium - to - large esophageal variceal bleeding, and the application of endoscopic rubber band ligation (EBL) in cases of drug treatment intolerance or contraindications. The paper also discussed different assessment methods for portal hypertension, including hepatic venous pressure gradient (HVPG) measurement, biochemical tests, Doppler ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and non - invasive measurement methods of liver and spleen stiffness, which are of great significance for diagnosing and monitoring the severity of portal hypertension. Overall, the paper emphasizes that stratifying the risk of patients with liver cirrhosis according to the severity of portal hypertension and adopting individualized treatment strategies can improve the treatment effect and the survival rate of patients.